David Rodman, M.D.

David Rodman, M.D.

Chief Medical OfficeratMineralys Therapeutics· In proxies 2022–2025

Pay in FY2025-23% from the year before · Mineralys Therapeutics stock +194.8% the same year

David Rodman, M.D. was paid $2.2M in FY2025 (Dec), down 23%. Mineralys Therapeutics stock rose 194.8% that year.

Pay$100 in the stock at the end of FY23 → $422
Pay is from the Summary Compensation Table of each Mineralys Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Mineralys TherapeuticsPublic company · 4 yr
    • Chief Medical Officer2022 – Present · 4 yrStock in role +16%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?